FRANK J. BELLIZZI, DMD
Chief Executive Officer
Frank Bellizzi has over 25 years of experience, within and beyond Life Sciences, as an operator, consultant and advisor leading business transformation and growth. Immediately prior to Concentric, Dr. Bellizzi was CEO of HydraDx, a saliva-based platform for real time health monitoring using a connected device. Dr. Bellizzi also served as President of Zila Pharmaceuticals (NASDAQ: ZILA) where he successfully created and implemented a strategy to build an oral cancer detection business, growing its flagship product, ViziLite® Plus, into the leading oral cancer detection test in the U.S. and internationally.
In addition, as Chief Financial Officer and Chief Operating Officer of Streampipe, a rich media software company, Dr. Bellizzi engineered all aspects of the company’s growth and successful sale to Loudeye (NASDAQ: LOUD).
Earlier in his career, as a member of Booz, Allen & Hamilton’s Health Industries Practice, Dr. Bellizzi facilitated a number of high-profile engagements, including the merger and integration of two leading West Coast health systems, the acquisition strategy for a leading New York health system, and the operational revitalization of the Australian health care system.
Dr. Bellizzi earned his MBA from the Wharton School of the University of Pennsylvania, his DMD from the University of Pennsylvania School of Dental Medicine, and his BS from Georgetown University.
JOHN DONOVAN, MD
Founder & President
John Donovan is a board certified anesthesiologist with 25 years of experience in clinical medicine and 14 years of experience working with life science companies Dr. Donovan has held a number of senior business development positions for anesthesia/pain biotechs, including Signature Therapeutics and Anesiva (NASDAQ: ANSV).
Previously, Dr. Donovan built and ran a large anesthesiology medical practice, East Bay Anesthesiology Medical Group, which provides anesthesia and perioperative medical services to hospitals in the Sutter Health system. Dr. Donovan has conducted research and published on postsurgical pain management, including the use of continuous peripheral nerve blocks for TKA, and has also served as an advisor to a variety of emerging life science businesses. Dr. Donovan completed his residency in anesthesiology at the University of California San Francisco where he was chief resident and continues to maintain a faculty appointment. He served as a diving medical officer in the U.S. Navy and has been involved with global health efforts in Haiti since the 2010 earthquake.
Dr. Donovan earned BS and MD degrees from Georgetown University and an MBA from the Haas School of Business at the University of California Berkeley.
SUSAN KRAMER, DrPH
Executive Vice President Program Management and Strategy
Susan Kramer has more than 30 years experience in biopharmaceutical research and development, the first 18 with Genentech. She was a co-founder of Corthera, Inc. and has held senior management roles at a number of biotech companies, including XOMA and Anesiva. She most recently served as Vice President of Product Development at Annexon Biosciences.
Dr. Kramer received a BA from College of St. Scholastica and earned her MPH and DrPH in Biomedical Sciences from the University of California Berkeley.
MIKE ROYAL, MD JD MBA
Chief Medical Officer
Mike Royal has 17 years of pain drug development and medical affairs experience particularly in 505(b)(2) NDAs across several indications, but also with NCEs and generics. He has held senior clinical roles at Liquidia Technologies, Sorrento Therapeutics, AcelRx Pharmaceuticals, Cadence Pharmaceuticals, Solstice Neuroscience, Alpharma and Elan Biopharmaceuticals.
Dr. Royal holds Board certifications in Internal Medicine, Anesthesiology, Addiction Medicine and Pain Medicine with 12 years of medical practice experience in both academic and private practice settings. He has over 185 peer-reviewed publications, book chapters, and abstracts/posters.
Dr. Royal received a BS in synthetic organic chemistry from MIT, MD from University of Massachusetts, JD from University of Maryland and MBA from TRIUM (NYU Stern School, London School of Economics, HEC-Paris).
CRAIG HUSFELD, PhD
Chief Scientific Officer
Craig Husfeld is a synthetic and medicinal chemist with 15 years of pharmaceutical experience. Dr. Husfeld has successfully overseen the synthetic and medicinal chemistry and early-stage CMC work for multiple development stage biotech companies in the analgesic space, including as Director of Medicinal Chemistry at Elysium Therapeutics where he has focused on creating diversion-resistant opioid drug formulations.
From 2008 to 2014, Dr. Husfeld was Director of Chemistry at Signature Therapeutics (Pharmacofore), where he led the development of abuse- deterrent opioid prodrugs. Prior to his role at Signature, Dr. Husfeld served as a senior researcher at Theravance.
Dr. Husfeld received a BS in chemistry from University of California, Riverside and a PhD in synthetic organic chemistry from Stanford University.
RICHARD LOWENTHAL, MS, MBA
Head of Regulatory
Richard Lowenthal has over 25 years of Medicinal Product Development, Regulatory Affairs and Quality Assurance experience in various roles at both small and large biopharmaceutical companies and has participated in the submission of over 20 applications for approval of new pharmaceutical products during his career.
Mr. Lowenthal, as a past FDA reviewer in both the Division of Neuropharmacology Drug Products and Division of Oncology at the US FDA, has direct experience working within the Agency that facilitates interactions and an understanding of the FDA perspective.
Mr. Lowenthal was Vice President, Regulatory Affairs and Quality Assurance for Cadence Pharmaceuticals and has held senior regulatory roles at Maxim, AnGes, MG, Janssen and Somerset Pharma. Currently, co-founder of Pacific-Link Regulatory Consulting, M.S. in Organic Chemistry from Florida State University and Masters in Business Science for Executive Leadership from the University of San Diego.
SUE WOLLOWITZ, PhD
Head of CMC
Sue Wollowitz has more than 30 years of experience in pharmaceutical development. She led CMC and Pharmaceutical Operations at Medivation, Inc. for 8 years and previously held a similar position at Cerus Corporation. She has also worked in discovery research at Dow Chemical Company. She has taught at UC Berkeley Extension, is the holder of 32 patents, and the author of over 20 publications, most recently writing on pharmaceutical development issues.
Dr. Wollowitz has a PhD in organic chemistry from the University of Wisconsin at Madison and further trained at CNRS in France and at the University of Chicago.